Absci Announces Pricing of Public Offering of Common Stock

Absci Announces Pricing of Public Offering of Common Stock

VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed with generative AI, today announced the pricing of an underwritten public offering of 16,670,000 shares of its common…

AI Drug Discovery Firm Absci Raises $50M in Public Offering with Morgan Stanley, JP Morgan Leading

Clinical-stage AI biotech prices 16.67M shares, backed by top Wall Street firms. Proceeds to advance breakthrough drug development platform. See offering details.